Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Ensifentrine

Respiratory

Respiratory Today—April 24, 2026

This week’s Respiratory Research update highlights regulatory approvals,…

Respiratory

Respiratory Video Recap—February 6, 2026

This biweekly Respiratory Video Recap highlights regulatory actions, clinical…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
LucidWargames
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Respiratory Today—May 8, 2026
Vaccines Today—May 8, 2026
Public Health Today—May 8, 2026
Lucid Diligence Brief: Lucent Diagnostics and Tempus AI Partnership
Lucid Diligence Brief: Blackstone Life Sciences $250 million investment in Anagram Therapeutics

Tags

9MW2821 510(k) Addex Therapeutics Arialys Ascendis Pharma Bicara Therapeutics CartiLife CNSide CSF assay de-identification DELIVER DM1 Efsubaglutide Alfa Etana Evaxion Fitbit Air FKRP GHD gut virome Immuncell-LC Injection Liafensine McCune-Albright Syndrome MD Codes Menopause hormone therapy mesothelin Nipocalimab-Aahu NVIDIA Blackwell ovarian cancer research PureTech Health Qure.ai Replay SaMD sHLH Soligenix strabismus Tavneos TCR therapy TnpB transcatheter implant ublituximab-xiiy Unstable Angina Utah Medical Licensing Board Vertex VitriVax Women’s Health Access Ziihera

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Respiratory Today—May 8, 2026
Vaccines Today—May 8, 2026
Public Health Today—May 8, 2026
Lucid Diligence Brief: Lucent Diagnostics and Tempus AI Partnership
Lucid Diligence Brief: Blackstone Life Sciences $250 million investment in Anagram Therapeutics

TAGS

9MW2821 510(k) Addex Therapeutics Arialys Ascendis Pharma Bicara Therapeutics CartiLife CNSide CSF assay de-identification DELIVER DM1 Efsubaglutide Alfa Etana Evaxion Fitbit Air FKRP GHD gut virome Immuncell-LC Injection Liafensine McCune-Albright Syndrome MD Codes Menopause hormone therapy mesothelin Nipocalimab-Aahu NVIDIA Blackwell ovarian cancer research PureTech Health Qure.ai Replay SaMD sHLH Soligenix strabismus Tavneos TCR therapy TnpB transcatheter implant ublituximab-xiiy Unstable Angina Utah Medical Licensing Board Vertex VitriVax Women’s Health Access Ziihera

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy